1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
Adenocarcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Recurrence (1)
Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Disease Attributes (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Complex and Mixed (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Squamous Cell (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1)
Cyclophosphamide (1) · Interleukin-2 (1) · Nivolumab (1) · aldesleukin (1) · fludarabine (1) · fludarabine phosphate (1)
H. Lee Moffitt Cancer Center and Research Institute (1)
United States (1)